Navrogen Closes $3.0M Seed Financing To Advance Its Preclinical Pipeline Targeting Humoral Immunosuppressed Cancers And Immune-Related Disorders
Amount Raised
$3 Million
Round Type
seed
Description
Navrogen, Inc., a privately held preclinical biotechnology company, announced today that it has raised $3.0M from an equity financing to support its Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. HIO is a process by which tumors produce factors that suppress a patient's humoral immune response against malignant tissues. The major use of proceeds will focus on advancing the company's lead HIO-refractory, anti-mesothelin NAV-001 antibody drug conjugate program and its NK cell activator platforms that specifically address HIO suppressed cancers and immune-mediated diseases. The financing was led by Tellus BioVentures along with existing investors
FundzWatch™ Score
Buyer Intent Analysis
Get personalized insights on buying likelihood